TAS 3681Alternative Names: TAS3681
Latest Information Update: 04 Apr 2016
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 01 Mar 2016 Phase-I clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in United Kingdom (PO) (NCT02566772)
- 25 Sep 2015 Taiho Oncology plans a phase I trial for Prostate cancer (Metastatic disease) in USA and United Kingdom (NCT02566772)